185 related articles for article (PubMed ID: 12019162)
1. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
Carles-Kinch K; Kilpatrick KE; Stewart JC; Kinch MS
Cancer Res; 2002 May; 62(10):2840-7. PubMed ID: 12019162
[TBL] [Abstract][Full Text] [Related]
2. Differential EphA2 epitope display on normal versus malignant cells.
Coffman KT; Hu M; Carles-Kinch K; Tice D; Donacki N; Munyon K; Kifle G; Woods R; Langermann S; Kiener PA; Kinch MS
Cancer Res; 2003 Nov; 63(22):7907-12. PubMed ID: 14633720
[TBL] [Abstract][Full Text] [Related]
3. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
4. EphA2 overexpression causes tumorigenesis of mammary epithelial cells.
Zelinski DP; Zantek ND; Stewart JC; Irizarry AR; Kinch MS
Cancer Res; 2001 Mar; 61(5):2301-6. PubMed ID: 11280802
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
6. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ
Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274
[TBL] [Abstract][Full Text] [Related]
7. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
8. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.
Pratt RL; Kinch MS
Mol Cancer Res; 2003 Dec; 1(14):1070-6. PubMed ID: 14707290
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase.
Zelinski DP; Zantek ND; Walker-Daniels J; Peters MA; Taparowsky EJ; Kinch MS
J Cell Biochem; 2002; 85(4):714-20. PubMed ID: 11968011
[TBL] [Abstract][Full Text] [Related]
10. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
Jackson D; Gooya J; Mao S; Kinneer K; Xu L; Camara M; Fazenbaker C; Fleming R; Swamynathan S; Meyer D; Senter PD; Gao C; Wu H; Kinch M; Coats S; Kiener PA; Tice DA
Cancer Res; 2008 Nov; 68(22):9367-74. PubMed ID: 19010911
[TBL] [Abstract][Full Text] [Related]
11. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
12. EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.
Hu M; Carles-Kinch KL; Zelinski DP; Kinch MS
Mol Cancer Res; 2004 Oct; 2(10):533-40. PubMed ID: 15498927
[TBL] [Abstract][Full Text] [Related]
13. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
15. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase.
Zantek ND; Azimi M; Fedor-Chaiken M; Wang B; Brackenbury R; Kinch MS
Cell Growth Differ; 1999 Sep; 10(9):629-38. PubMed ID: 10511313
[TBL] [Abstract][Full Text] [Related]
17. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
[TBL] [Abstract][Full Text] [Related]
18. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
19. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
Brantley-Sieders DM; Fang WB; Hicks DJ; Zhuang G; Shyr Y; Chen J
FASEB J; 2005 Nov; 19(13):1884-6. PubMed ID: 16166198
[TBL] [Abstract][Full Text] [Related]
20. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
Nasreen N; Mohammed KA; Antony VB
Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
